- Home
- OPCH vs INDV Comparison
OPCH vs INDV Comparison
Compare OPCH & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | INDV |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.2B |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OPCH | INDV |
|---|---|---|
| Price | $31.13 | $35.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $30.03 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 6.0M | 1.6M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.25 | ★ 8100.00 |
| EPS | 0.29 | ★ 1.67 |
| Revenue | ★ $4,998,202,000.00 | $1,239,000,000.00 |
| Revenue This Year | $1.91 | $7.50 |
| Revenue Next Year | $6.41 | $5.07 |
| P/E Ratio | $107.24 | ★ $21.21 |
| Revenue Growth | ★ 16.17 | 4.29 |
| 52 Week Low | $18.01 | $23.72 |
| 52 Week High | $36.80 | $42.81 |
Technical Indicators
Market Signals| Indicator | OPCH | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 83.97 | 43.62 |
| Support Level | $30.86 | $33.45 |
| Resistance Level | $36.64 | $35.54 |
| Average True Range (ATR) | 0.30 | 0.96 |
| MACD | 0.76 | -0.00 |
| Stochastic Oscillator | 99.55 | 12.05 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).